These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29753163)

  • 1. Baseline Renal Function and Albumin are Powerful Predictors for Allogeneic Transplantation-Related Mortality.
    Shouval R; de Jong CN; Fein J; Broers AEC; Danylesko I; Shimoni A; Reurs MR; Baars AE; van der Schaft N; Nagler A; Cornelissen JJ
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1685-1691. PubMed ID: 29753163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation.
    Vaughn JE; Storer BE; Armand P; Raimondi R; Gibson C; Rambaldi A; Ciceri F; Oneto R; Bruno B; Martin PJ; Sandmaier BM; Storb R; Sorror ML
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1418-24. PubMed ID: 25862589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
    Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation.
    Berro M; Arbelbide JA; Rivas MM; Basquiera AL; Ferini G; Vitriu A; Foncuberta C; Fernandez Escobar N; Requejo A; Milovic V; Yantorno S; Szelagoswki M; Martinez Rolon J; Bentolila G; Garcia JJ; Garcia P; Caeiro G; Castro M; Jaimovich G; Palmer S; Trucco JI; Bet LA; Shaw BE; Kusminsky GD
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1646-1650. PubMed ID: 28669923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
    Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
    Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Aladağ E; Demiroğlu H; Büyükaşık Y; Göker H
    Turk J Haematol; 2021 Jun; 38(2):138-144. PubMed ID: 32539316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study.
    Murthy HS; Sheets K; Kumar A; Nishihori T; Mina A; Chavez JC; Ayala E; Field T; Mathews J; Locke F; Perez L; Betts BC; Khimani F; Miladinovic B; Tsalatsanis A; Ochoa-Bayona JL; Alsina M; Fernandez H; Pidala J; Anasetti C; Kharfan-Dabaja MA
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):400-405. PubMed ID: 29032266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.
    Nakaya A; Mori T; Tanaka M; Tomita N; Nakaseko C; Yano S; Fujisawa S; Sakamaki H; Aotsuka N; Yokota A; Kanda Y; Sakura T; Nanya Y; Saitoh T; Kanamori H; Takahashi S; Okamoto S
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1553-9. PubMed ID: 25034961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation.
    Veeraputhiran M; Yang L; Sundaram V; Arai S; Lowsky R; Miklos D; Meyer E; Muffly L; Negrin R; Rezvani A; Shizuru J; Weng WK; Johnston L
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1744-1748. PubMed ID: 28668491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources.
    Elsawy M; Storer BE; Milano F; Sandmaier BM; Delaney C; Salit RB; Rashad AH; Woolfrey AE; Appelbaum FR; Storb R; Sorror ML
    Biol Blood Marrow Transplant; 2019 May; 25(5):1045-1052. PubMed ID: 30500442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation.
    Shibasaki Y; Suwabe T; Katagiri T; Tanaka T; Ushiki T; Fuse K; Sato N; Yano T; Kuroha T; Hashimoto S; Narita M; Furukawa T; Sone H; Masuko M
    Int J Hematol; 2018 Sep; 108(3):282-289. PubMed ID: 29744806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34
    Barba P; Ratan R; Cho C; Ceberio I; Hilden P; Devlin SM; Maloy MA; Barker JN; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Ponce DM; Sauter C; Tamari R; van den Brink MRM; Young JW; O'Reilly RJ; Giralt SA; Perales MA
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):67-74. PubMed ID: 27789361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation.
    Shouval R; Fein JA; Shouval A; Danylesko I; Shem-Tov N; Zlotnik M; Yerushalmi R; Shimoni A; Nagler A
    Blood Adv; 2019 Jun; 3(12):1881-1890. PubMed ID: 31221661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
    Acosta-Medina AA; Baranwal A; Johnson IM; Kharfan-Dabaja MA; Murthy H; Palmer JM; Sproat L; Mangaonkar A; Shah MV; Hogan WJ; Litzow MR; Tefferi A; Alkhateeb HB
    Transplant Cell Ther; 2023 Jun; 29(6):360.e1-360.e8. PubMed ID: 36773650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation.
    Rondon-Clavo C; Scordo M; Hilden P; Shah GL; Cho C; Maloy MA; Papadopoulos EB; Jakubowski AA; O'Reilly RJ; Gyurkocza B; Castro-Malaspina H; Tamari R; Shaffer BC; Perales MA; Jaimes EA; Giralt SA
    Biol Blood Marrow Transplant; 2018 Dec; 24(12):2517-2522. PubMed ID: 30055353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants.
    Majhail NS; Brunstein CG; McAvoy S; DeFor TE; Al-Hazzouri A; Setubal D; Arora M; Le CT; Wagner JE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):985-992. PubMed ID: 18721761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.
    Farhadfar N; Dias A; Wang T; Fretham C; Chhabra S; Murthy HS; Broglie L; D'Souza A; Gadalla SM; Gale RP; Hashmi S; Al-Homsi AS; Hildebrandt GC; Hematti P; Rizzieri D; Chee L; Lazarus HM; Bredeson C; Jaimes EA; Beitinjaneh A; Bashey A; Prestidge T; Krem MM; Marks DI; Benoit S; Yared JA; Nishihori T; Olsson RF; Freytes CO; Stadtmauer E; Savani BN; Sorror ML; Ganguly S; Wingard JR; Pasquini M
    Transplant Cell Ther; 2021 May; 27(5):410-422. PubMed ID: 33775617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
    Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):66-72. PubMed ID: 24141006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
    Carré M; Porcher R; Finke J; Ehninger G; Koster L; Beelen D; Ganser A; Volin L; Lozano S; Friis L; Michallet M; Tischer J; Olavarria E; Cascon MJP; Iacobelli S; Koc Y; Jindra P; Arat M; de Witte T; Yakoub Agha I; Kröger N; Robin M
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):451-457. PubMed ID: 31647984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.